难治性丙型肝炎再认识—谈丙型肝炎抗病毒治疗策略的进展

窦晓光; 丁洋

doi:10.3969/j.issn.1001-5256.2014.06.002

难治性丙型肝炎再认识—谈丙型肝炎抗病毒治疗策略的进展

DOI: 10.3969/j.issn.1001-5256.2014.06.002

窦晓光,
丁洋

中国医科大学附属盛京医院感染科

详细信息

中图分类号: R512.63
计量
- 文章访问数: 209
- HTML全文浏览量: 21
- PDF下载量: 123
- 被引次数: 0
出版历程
- 收稿日期: 2014-04-06
- 出版日期: 2014-06-20

Re- understanding of refractory hepatitis C: progress in antiviral therapy strategies for hepatitis C

Department of Infectious Diseases, Shengjing Hospital Affiliated to China Medical University

摘要

摘要: 丙型肝炎从病毒的发现、临床诊断,到干扰素抗病毒治疗经历了近20年的历程,取得了非常显著的成绩。从最初的单纯控制病毒,到目前的临床治愈;从单一普通干扰素治疗持续病毒学应答（SVR）率30%左右,到目前我国聚乙二醇干扰素联合利巴韦林标准治疗的SVR率70%80%,从依赖基因型和病毒载量定义治疗的难易性,到根据宿主IL-28基因型及应答模式（RVR、cEVR）决定治疗策略,特别是近几年直接抗病毒药物的不断问世,使丙型肝炎的抗病毒治疗不论从理念上,还是临床治疗策略上都有了根本的改变。从对难治性丙型肝炎的再认识出发,系统综述丙型肝炎抗病毒治疗策略的进展。
- 丙型肝炎 /
- 抗病毒药 /
- 综述
Abstract: It has been nearly 20 years from the discovery of hepatitis C virus ( HCV) and clinical diagnosis of hepatitis C to antiviral therapy with interferon, and significant progress has been made. Substantial changes have taken place in both the concept and strategy for antiviral treatment of hepatitis C, with more and more direct- acting antiviral agents emerging in recent years; these changes are as follows: from the control of HCV to clinical cure, from a sustained virologic response ( SVR) rate around 30% with conventional interferon therapy to an SVR rate of 70%- 80% with standard therapy with pegylated interferon and ribavirin, and from evaluating the difficulty of treatment based on genotypes and viral load to determining the treatment strategy according to host IL28B genotypes and response patterns ( rapid virologic response and complete early virologic response) . The progress in antiviral therapy strategies for hepatitis C is systematically reviewed for re-understanding of refractory hepatitis C.
- hepatitis C /
- antiviral agents /
- review

HTML全文

参考文献(25)

[1]DOU XG.The relevant factors and strategies related efficacy with standard of care in chronic hepatitis C treatment naive patients[J].Chin J Hepatol, 2013, 21 (6) :406-407. (in Chinese) 窦晓光.影响丙型肝炎初治患者标准化治疗疗效的相关因素及对策[J].中华肝脏病杂志, 2013, 21 (6) :406-407.

[2]FRIED MW, SHIFFMAN ML, RDEEY KR, et al.Peginterferon alpha-2a plus ribavirin for chronic hepatitis C virus infection[J].N Engl J Med, 2002, 347 (13) :975-982.

[3]JENSEN DM, MORGAN TR, MARCELLIN P, et al.Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd) /ribavirin therapy[J].Hepatology, 2006, 43 (5) :954-960.

[4] European Association for the Study of the Liver.EASL Clinical Practice Guidelines:management of hepatitis C virus infection[J].J Hepatol, 2011, 55 (2) :245-264.

[5]GHANY MG, NELSON DR, STRADER DB, et al.An update on treatment of genotype 1 chronic hepatitis C virus infection:2011practice guideline by the American Association for the Study of Liver Diseases[J].Hepatology, 2011, 54 (4) :1433-1444.

[6]MYERS RP, RAMJI A, BILODEAU M, et al.An update on the management of hepatitis C:consensus guidelines from the Canadian Association for the Study of the Liver[J].Can J Gastroenterol, 2012, 26 (6) :359-375.

[7] BRUNO S, SHIFFMAN ML, ROBERTS SK, et al.Efficacy and safety of peginterferon alfa-2a (40KD) plus ribavirin in hepatitis C patients with advanced fibrosis and cirrhosis[J].Hepatology, 2010, 51 (2) :388-397.

[8]MOUSA O, PHAM LE, EGWIM CI, et al.Efficacy, tolerability and discontinuations of the current direct acting agents in chronic hepatitis C patients with cirrhosis[J].Hepatology, 2012, 56 (Suppl 4) :1049A.

[9]SAAB S, HUNT DR, STONE MA, et al.Timing of hepatitis C antiviral therapy in patients with advanced liver disease:a decision analysis model[J].Liver Transpl, 2010, 16 (6) :748-759.

[10]PRATI GM, RUMI M, AGHEMO A, et al.The influence of liver fibrosis on the outcome of pegylated interferon and ribavirin antiHCV therapy:a sub-analysis of the MIST study[J].Hepatology, 2009, 50 (Suppl 4) :687A.

[11]VEZALI E, AGHEMO A, COLOMBO M.A review of the treatment of chronic hepatitis C virus infection in cirrhosis[J].Clin Ther, 2010, 32 (13) :2117-2138.

[12]BRUNO S, SHIFFMAN ML, ROBERTS SK, et al.Efficacy and safety of peginterferon alfa-2a (40KD) plus ribavirin in hepatitis C patients with advanced fibrosis and cirrhosis[J].Hepatology, 2010, 51 (2) :388-397.

[13]ZEUZEM S, PAWLOTSKY JM, LUKASIEWICZ E, et al.International, multicenter, randomized, controlled study comparing dynamically individualized versus standard treatment in patients with chronic hepatitis C[J].J Hepatol, 2005, 43 (2) :250-257.

[14]DAVIS GL, WONG JB, MCHUTCHISON JG, et al.Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C[J].Hepatology, 2003, 38 (3) :645-652.

[15]FERENCI P, FRIED MW, SHIFFMAN ML, et al.Predicting sustained virological response in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD) /ribavirin[J].J Hepatol, 2005, 43 (3) :425-433.

[16]YU JW, WANG GQ, SUN LJ, et al.Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin[J].J Gastroenterol Hepatol, 2007, 22 (6) :832-836.

[17]ROMERO-GMEZ M, DEL MAR VILORIA M, ANDRADE RJ, et al.Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients[J].Gastroenterology, 2005, 128 (3) :636-641.

[18]CALVARUSO V, MAZZA M, ALMASIO PL.Pegylated-interferon-α (2a) in clinical practice:how to manage patients suffering from side effects[J].Expert Opin Drug Saf, 2011, 10 (3) :429-435.

[19]FREDLUND P, HILLSON JL, GRAY TE, et al.Peginterferon lambda-1a is associated with less autoimmune thyroid disease and serious autoimmune disease than peginterferonα-2a when used in combination with RBV for the treatment of chronic hepatitis C virus infection[J].Hepatology, 2012, 56 (Suppl 4) :571A.

[20]MUIR AJ, SRINIVASAN S, SAPRA S, et al.Peginterferon lambda-1a is less likely to induce clinically significant neuropsychiatric sympotoms during the treatment of chronic hepatitis C virus infection, compared to peginterferonα-2a[J].Hepatology, 2012, 56 (Suppl 4) :578A.

[21]POORDAD F, McCONE J JR, BACON BR, et al.Boceprevir for untreated chronic HCV genotype 1 infection[J].N Engl J Med, 2011, 364 (3) :1195-1206.

[22]BRUNO S, VIERLING JM, ESTEBAN R, et al.Efficacy and safety of boceprevir plus peginterferon-ribavirin in patients with HCV G1 infection and advanced fibrosis/cirrhosis[J].J Hepatology, 2013, 58 (3) :479-487.

[23]BACON BR, GORDON SC, LAWITZ E, et al.Boceprevir for previously treated chronic HCV genotype 1 infection[J].N Engl J Med, 2011, 364 (13) :1207-1217.

[24]SHERMAN KE, FLAMM SL, AFDHAL NH, et al.Response-guided telaprevir combination treatment for hepatitis C virus infection[J].N Engl J Med, 2011, 365 (11) :1014-1024.

[25]POODAD F, FRIED MW, ZEUZEM S, et al.Efficacy and tolerability of TMC435 150 mg once daily with peginterferonα-2a and ribavirin for treatment of HCV genotype 1 infection in patients with Metavir score F3 and F4 (PILLAR and ASPIRE trials) [J].Hepatology, 2012, 56 (Suppl 4) :233A.

施引文献

资源附件(0)

访问统计